BRCA1 Promoter CpG Methylation in Breast Cancer: A Pilot Study in African Women
Open Access
Abstract
Background: Breast cancer susceptibility gene 1 (BRCA1) is a pivotal regulator of DNA repair, and its loss through germline mutations is strongly linked to the development of aggressive breast cancers with characteristic clinical and pathological features. Beyond genetic disruption, epigenetic silencing via promoter hypermethylation has emerged as a non-mutational mechanism of tumour suppressor inactivation and a potential biomarker for guiding therapeutic decisions. Here, we investigate BRCA1 promoter methylation, its impact on gene expression, and its association with clinicopathological features in a cohort of African women with breast cancer. Methods: Matched tumour and adjacent normal tissues from 27 Black African women with breast cancer were analysed for BRCA1 promoter methylation and gene expression using bisulfite pyrosequencing and quantitative real-time PCR. Associations with clinicopathological variables were assessed using Spearman’s correlation analyses. Results: Five CpG sites within the BRCA1 promoter were significantly hypermethylated in breast tumours compared with matched adjacent normal tissues and showed an inverse association with BRCA1 mRNA expression. Elevated promoter methylation was enriched in hormone receptor-negative and triple-negative breast cancer subtypes and was not influenced by neoadjuvant chemotherapy. BRCA1 promoter methylation occurred independently of BRCA1 mutational status. No significant associations were observed between BRCA1 methylation and age, body mass index, smoking status, or alcohol consumption. Conclusions: Our findings provide evidence of BRCA1 epigenetic silencing in breast tumours from African women, particularly within aggressive hormone receptor-negative subtypes. These results suggest that BRCA1 promoter methylation may represent a clinically informative biomarker for patient stratification and highlight the importance of validation in larger, population-representative cohorts before clinical translation.Keywords
Funding Information
- South African Medical Research Council
- National Research Foundation (23030881391)
This publication has 61 references indexed in Scilit:
- BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitorsBreast Cancer Research and Treatment, 2024
- Recent trends in hereditary breast cancer incidence by race and age in KwaZulu‐Natal, South Africa: An 11‐year single‐centre retrospective study (2011‐2021)International Journal of Cancer, 2023
- Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian CancerJAMA Oncology, 2022
- Olaparib monotherapy as primary treatment in unselected triple negative breast cancerAnnals of Oncology, 2021
- BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapyBreast Cancer Research and Treatment, 2020
- Breast cancer in Sub-Saharan Africa: opportunities for preventionBreast Cancer Research and Treatment, 2014
- Pyrosequencing analysis of BRCA1 methylation level in breast cancer cellsTumor Biology, 2013
- BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtypeCancer and Metastasis Reviews, 2011
- Epigenetic silencing of the tumor suppressor klotho in human breast cancerBreast Cancer Research and Treatment, 2011
- BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profilesBreast Cancer Research and Treatment, 2005